How's Annette doing??
- Thread starter Anonymous
- Start date
-
- Tags
- None
Very early days so you ain't seen nothin yet.... just ask any of the lot she made redundant at Pfizer!!
She'll fit right in - just saw her speak for 1h without actually saying anything 
She seems to be doing OK, certainly has plans. IMS's days are numbered it seems from early comments. She had no doubt been lined up to take over from JB in 4-5 years when he retires.
Baldoni's a real son of a bitch. He should of been fired a long time ago. A real empty suit, Know-nothing creep.
I agree, Annette would be better so far. Time will tell.
Annette's doing great. In project meetings, she is a great balance to Baldoni. If he's lucky, she'll stay around.
Annette is closing RTP. That is why she isn't visiting that site in her tour.
Congratulations to Ware and UM - sounds like these sites will stay open.
Congratulations to Ware and UM - sounds like these sites will stay open.
Maybe, maybe not. But if so, sorry for the folks, but long overdue for the organization.
I'd be interested to hear the rationale for closing the RTP site.
At RTP they're investing in the Evidence Based Formulations group, the Stiefel Dermatology R&D effort is being expanded, the secondary pilot plant is being improved, more collaborative work is being undertaken by PD/IMS with the GMS-Zebulon site, etc. You wouldn't think that all this would be underway for a site that's targeted for shutdown.
Granted, I may be making a gigantic assumption to think that PD/IMS management uses rational logic to make their decision. And yes, I hang my hat at RTP.
At RTP they're investing in the Evidence Based Formulations group, the Stiefel Dermatology R&D effort is being expanded, the secondary pilot plant is being improved, more collaborative work is being undertaken by PD/IMS with the GMS-Zebulon site, etc. You wouldn't think that all this would be underway for a site that's targeted for shutdown.
Granted, I may be making a gigantic assumption to think that PD/IMS management uses rational logic to make their decision. And yes, I hang my hat at RTP.
Annette did say that site closures were not part of this, rather site consolidation.
Maybe it's time some of the bloated sites lost some weight (i.e. Ware and UM).
Just testing the water before making some big changes
Regarding #11 post about "closing RTP" - - there was some scuttlebutt going around that most of Safety Assessment (SA) at RTP would be shuttered, and that the SA activities at UM and Ware will stay open.
No mention of other departments in the rumor.
No mention of other departments in the rumor.
Confirmed.
RTP SA is toast. Some survivors will be put in the non-GLP LAS group - cleaning rat shit from cages.
Come now. What reason would PW have to close UM? DMPK should do the same thing.
"investing" in EBF?
What investment has been made in EBF-RTP?
Wasn't EBF in RTP formed simply by moving most of the people in the RTP line extension group to the newly created EBF group?
As far as I know, not one new person was hired to be in EBF-RTP and not one person was hired to replace the people in line extension group.
I also don't believe that one penny has been spent on lab equipment or processing equipment or lab facilities or processing facilities.
Not sure how any of that adds up to an "investment."
Forming EBF was just another mindless reorg.
Trying to solve a problem by renaming a department. No true innovation in technology or development strategy.
And leaving a new trail of chaos and confusion and workload as routine processes have to be adapted to fit the new department.
Similar (not identical) situation for Stiefel. While the dust hasn't settled there yet, for the most part Stiefel is being staffed by rejects and outcasts from other PD groups (can you say "IPD") that have been cut. They are still talking about actually hiring people from outside of GSK to staff Stiefel so this may be a little different than EBF. But as of yet Stiefel is being built by cannibalizing other RTP departments.
I guess if your definition of investment includes cannibalization then yes, GSK is investing in RTP.
From were I sit, the only groups in PTS-RTP that are actually growing are the groups related to outsourcing management. And you don't have to be a pimple on Einstein's butt to figure out what that means.
What investment has been made in EBF-RTP?
Wasn't EBF in RTP formed simply by moving most of the people in the RTP line extension group to the newly created EBF group?
As far as I know, not one new person was hired to be in EBF-RTP and not one person was hired to replace the people in line extension group.
I also don't believe that one penny has been spent on lab equipment or processing equipment or lab facilities or processing facilities.
Not sure how any of that adds up to an "investment."
Forming EBF was just another mindless reorg.
Trying to solve a problem by renaming a department. No true innovation in technology or development strategy.
And leaving a new trail of chaos and confusion and workload as routine processes have to be adapted to fit the new department.
Similar (not identical) situation for Stiefel. While the dust hasn't settled there yet, for the most part Stiefel is being staffed by rejects and outcasts from other PD groups (can you say "IPD") that have been cut. They are still talking about actually hiring people from outside of GSK to staff Stiefel so this may be a little different than EBF. But as of yet Stiefel is being built by cannibalizing other RTP departments.
I guess if your definition of investment includes cannibalization then yes, GSK is investing in RTP.
From were I sit, the only groups in PTS-RTP that are actually growing are the groups related to outsourcing management. And you don't have to be a pimple on Einstein's butt to figure out what that means.